Veracyte Inc Aktie News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which patients with recurrent prostate cancer benefit from hormone therapy with apalutamide in addition to s...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men with recurrent prostate cancer will be presented at ASTRO 2025, the annual meeting of the American Society for Radiation Oncology. The ...

Veracyte, Inc. (NASDAQ:VCYT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Presentation Kallum Titchmarsh Equity Analyst Okay. I think we can get started.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting, taking place September 10-14 at the Westin Kierland in Scottsdale, Ariz. The large number of abstracts stems from Veracyte's extensive database of thyroid-nod...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time. A live audio webcast of the company's presentation will be available by visiting Veracyte's website at http://investor.veracyte.com/...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces New Study in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer.

Veracyte's Q2 results show strong revenue growth, margin expansion, and a robust cash position, reinforcing my long-term bullish outlook. Key growth drivers include Decipher's expansion, upcoming product launches, and a pipeline of catalysts through 2028 supporting sustained revenue increases. Risks remain: high valuation, competitive pressures, and reimbursement uncertainties could lead to vol...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test.